ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0156

Heat Exposure and Acute Care Utilization among Individuals with Rheumatic Conditions: A Time Series Framework for Identifying Delayed Associations
Abstract Number: 0157

Influence of Outpatient Clinic Visits on Receipt of the COVID-19 Vaccine among People with Autoimmune Rheumatic Diseases
Abstract Number: 0158

Association between newer COVID-19 vaccines and COVID-19 related hospitalizations among people with autoimmune rheumatic diseases in the U.S. National COVID Cohort Collaborative (N3C)
Abstract Number: 0159

Prenatal and Early-Life Environmental Exposures in Juvenile-Onset Systemic Autoimmune Rheumatic Diseases
Abstract Number: 0161

Risk Factors and Clinical Predictors of Lung Cancer in Systemic Sclerosis: A Matched Case-Control Study from a Michigan Cohort
Abstract Number: 0162

Clinical Relevance of Systematic Comorbidity Screening in Autoimmune and Inflammatory Diseases
Abstract Number: 0163

Trends in hospitalization and outcomes among patients admitted with Adult-onset Still’s disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)
Abstract Number: 0164

Online Patient Survey on the Impact of Extreme Weather Events on Autoimmune and Rheumatic Diseases
Abstract Number: 0165

Per-Protocol Analysis of the Effectiveness of GLP1 Agonists Against SGLT2 Inhibitors on Osteoarthritis Outcomes
Abstract Number: 0166

Effect of Air Pollution on Prevalence and Disease Activity of Rheumatoid Arthritis in the German Middle-aged Population from the NAKO Baseline Examination
Abstract Number: 0167

Geographic and Demographic Patterns of Rheumatoid Arthritis in the United States: Insights from GBD 2021
Abstract Number: 0168

Risk of hospitalization in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
Abstract Number: 0169

The High Disease Burden of Connective Tissue Disorder-Interstitial Lung Disease in the USA Demonstrates an Unmet Need for Earlier Diagnosis and Treatment
Abstract Number: 0170

Rheumatoid arthritis, serologic status and risk of heart failure: A national cohort study
Abstract Number: 0171

The Association Between Short-Term Trajectory Of Atmospheric Particulate Matter 10 (PM10) Concentration And Hyperuricemia

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].